News and Press

WILDOMAR RADIATION THERAPY CENTER NOW USING “GPS FOR THE BODY” FOR TREATMENT OF PROSTATE CANCER

Wildomar Radiation Therapy Center is the First in the Inland Empire to Offer New Precision-Guided Technology

WILDOMAR, CA — Wildomar Radiation Therapy Center, owned and operated by Manhattan Beach-based Vantage Oncology, Inc., announced today that it is the first cancer-care program in the Inland Empire, Orange and San Diego counties to provide prostate cancer patients access to the Calypso® 4D Localization System™ for use in prostate cancer radiation treatment.

This new form of technology, called GPS for the Body®, allows precision-guided radiation therapy delivery to the prostate with continuous, prostate-motion detection and monitoring. Essentially, Calypso tells the physician where the tumor location is at all times during daily radiation treatments.

Movement of prostate tumors can occur during and in between treatments as a result of body physiology. This daily organ motion can result in ineffective delivery of radiation and damage surrounding healthy tissues. Calypso was designed to “track” the location of the prostate tumor during oncology treatments to precisely and continuously target the delivery of the external beam to the position of the tumor.

“I am excited to be able to offer my prostate cancer patients this new advanced and accurate radiation technology” said Tara Washington, M.D., Medical Director of Wildomar and Redhawk Radiation Therapy Centers in Wildomar and Temecula. “We believe that patients are well educated in prostate cancer treatment options and seek the best treatment approach possible, while minimizing side-effects of therapy. The Calypso 4D, GPS based, localization and tracking system is the only technology available for proving accuracy during each treatment.”

The major components of the Calypso System are called implanted Beacon® electromagnetic transponders. Each implanted Beacon® transponder is about the size of a small grain of rice. Three Beacon® transponders are implanted in the patient’s prostate prior to the delivery of radiation therapy treatments and they work in tandem with the other two main components, the Calypso System and the 4D Tracking Station™, to accurately and continuously locate the tumor in the prostate during radiation treatments.

“New technologies such as the Calypso System allows delivery of higher doses of radiation with fewer complications and side effects than patients have typically experienced when treated with conventional radiation therapy,” added Dr. Washington. “With the multi-disciplinary approach to treating malignancies today, our new technology will undoubtedly result in optimal results for the patient.

ABOUT VANTAGE ONCOLOGY, INC.
Founded in October 2002, Manhattan Beach, California-based Vantage Oncology, Inc. acquires, joint ventures, develops and operates state-of-the-art radiation oncology centers. Vantage Oncology was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Vantage Oncology is led by a seasoned management team, including Chief Executive Officer Michael Fiore, Medical Director Leslie Botnick, M.D., Chief Financial Officer Marshal Salomon and Chief Development Officer Mark Ahern. For more information about Vantage Oncology, visit www.vantageoncology.com.

ABOUT CALYPSO® MEDICAL TECHNOLOGIES, INC.
Calypso® Medical Technologies, Inc. (“Calypso”) is a Seattle, WA based privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately, and objectively pinpoint the location of tumors for improved accuracy in radiation therapy. Calypso Medical addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. In addition, the Calypso® 4D Localization System™’s non-ionizing electromagnetic guidance has the potential to improve work flow efficiency and treatment room utilization. The technology is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, head, neck and other radiation therapy target organs. The transponder is FDA 510(k) cleared for use in the prostate.Calypso®, Beacon®, and GPS for the Body® are registered trademarks, and Motion Matters™, On Target, On With Living™, Beacon Within™, 4D Localization System™, 4D Console™, 4D Electromagnetic Array™ and 4D Tracking Station™ are trademarks of Calypso® Medical Technologies, Inc.

CONTACTS:

Trace Longo
Longo Communications
(714) 600-9811

Vantage Oncology, Marketing Dept.
email:info@vantagoncology.com